Wave Life Sciences Ltd (WVE) News

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Wave Life Sciences Highlights Strategic Priorities and Expected 2025 Milestones Ahead of J.P. Morgan Presentation

Entering 2025 having demonstrated rapid translation of genetic insights to positive clinical data; advancing...

Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity

WVE-007 is a novel approach for treating obesity and is designed to silence INHBE to achieve healthy...

Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage...

Form 4 - Statement of changes in beneficial ownership of securities

Wave Life Sciences to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage...

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Wave Life Sciences to Present at Jefferies London Healthcare Conference

CAMBRIDGE, Mass., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage...

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]